Smoking Research Today is a free monthly online journal that collates and summarizes the latest research about Smoking, including details on cigarettes, cancer, lung, tar, nicotine.

Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study.

Feng B, Obach RS, Burstein AH, Clark DJ, de Morais SM, Faessel HM

Department of Pharmacokinetics, Pharmacodynamics, Drug Metabolism, Pfizer Global Research & Development, Groton, Connecticut, USA.

Varenicline is predominantly eliminated unchanged in urine, and active tubular secretion partially contributes to its renal elimination. Transporter inhibition assays using human embryonic kidney 293 cells transfected with human renal transporters demonstrated that high concentrations of varenicline inhibited substrate uptake by hOCT2 (IC(50)=890 microM), with very weak or no measurable interactions with the other transporters hOAT1, hOAT3, hOCTN1, and hOCTN2. Varenicline was characterized as a moderate-affinity substrate for hOCT2 (K(m)=370 microM) and its hOCT2-mediated uptake was partially inhibited by cimetidine. Co-administration of cimetidine (1,200 mg/day) reduced the renal clearance of varenicline in 12 smokers, resulting in a 29.0% (90% CI: 21.5%-36.9%) increase in systemic exposure. This increase is not considered clinically relevant, as it should not give rise to safety concerns. Consequently, it can be reasonably expected that other inhibitors of hOCT2 would not cause greater renal interactions with varenicline than that seen with the efficient hOCT2 inhibitor cimetidine.

Published 19 March 2008 in Clin Pharmacol Ther, 83(4): 567-76.
Full-text of this article is available online (may require subscription).

© 2006-2008 Smoking Research Today. All Rights Reserved.